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ABSTRACT 
Objective: To design, synthesize, in vitro Vascular Endothelial Growth Factor Receptor (VEGFR-2) assay, antiproliferative activity an Absorption, 
Distribution, Metabolism, Excretion and Toxicity (ADMET) studies of some novel bromoisatin incorporated isoxazole derivatives. 
Methods: Designed compounds were synthesized by the condensation of different 3-aryl-5-methylisoxazole-4-carbohydrazides (5a-h) with 5-bromoisatin 
to give the target molecules. To predict the affinity and activity of the ligand molecule the docking program GOLD 3.1 was employed to generate different 
bioactive binding poses of designing molecules at the active site of protein VEGFR-2. All the synthesized compounds were characterized based on the spectral 
and elemental analysis data. Antiproliferative activity performed against Human Umbilical vein endothelial cells (HUVEC cell line). 
Results: All the synthesized compounds showed the characteristic peaks in FTIR, 1H, C13NMR and Mass spectral analysis. In molecular docking, all 
the synthesized compounds (6a-j) exhibited high fitness scores with minimum three bonding interaction with the active site VEGFR-2 kinase. In in-
vitro, VEGFR-2 kinase assay, compounds 6a, 6b, 6d and 6e exhibited more than 70% inhibition at a single dose concentration of 5μM. In 
antiproliferative assay against HUVEC cell lines, compounds 6d and 6e exhibited potent activity with IC50 values in nanomolar concentrations. 
ADMET results of 6a, 6b, 6d and 6e are quite promising with least hepatotoxicity and good bioavailability. 
Conclusion: The derivatives were synthesized in quantitative yields. New derivatives posses antiproliferative activity, least hepatotoxicity and good 
bioavailability. 
Keywords: Bromo isatin, Isoxazole hydrazides, Molecular Docking, VEGFR-2 Kinase enzyme assay, In vitro antiproliferative assay, ADMET study 




Cancer is the leading cause of the deaths worldwide. Hence there is a 
need to develop new drugs to treat this life threatening disease 
without side effects. In recent years, isoxazoles derivatives have 
acquired significance due to their wide spectrum of biological 
activities such as anticancer [1], antibacterial [2], anti-inflammatory 
[3], anticonvulsant [4], anti-tubercular [5], antiviral [6], antioxidant 
[7], hypoglycemic [8] and antimicrobial activities [9] on the other hand 
isatin derivatives has attained much attention due to considerable 
pharmacological actions such as antimicrobial [10], antiviral [11], 
anticonvulsant [12] and anticancer [13] activities and Alzheimer's 
disease [14]. Tyrosine kinase inhibitors [15] are an important class of 
anti-cancer drugs that act by interfering with specific cell signaling 
pathways. Among the tyrosine kinases, VEGFR-2 Kinase [16] 
represents an important target since it plays a central role in 
angiogenesis. Thus, inhibition of VEGFR-2 signaling pathway is 
considered to be an attractive target while designing new anti-cancer 
molecules [17]. In the present study, while designing target molecules 
we have followed hybridization approach where isoxazole heterocycle 
is conjugated with isatin scaffold in order to obtain new hybrid 
molecules with potent VEGFR-2 inhibitor activity. The design of target 
molecules is presented in fig 1. Further, the designed molecules were 
computationally docked into VEGFR-2 kinase enzyme (PDB: 4AG8) 
using GOLD 3.1 software in order to gain some structural insights into 
the binding mode of designing molecules. The compounds that 
demonstrated a high fitness score in comparison with the reference 
drug, semaxanib and are further planned to screen for in vitro VEGFR-
2 kinase assay [18] and anti-proliferation study against Human 
Umbilical Vein Endothelial Cells (HUVEC) [19]. 
 
 
Fig. 1: Design of target molecules 
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MATERIALS AND METHODS 
Chemistry 
All the solvents and chemicals used in synthesis were AR and 
synthetic grade obtained from SD fine chemicals, E. Merck (India) 
and Aldrich Chemicals (India). The reactions were monitored by 
analytical thin layer chromatography (TLC) using E. Merck 0.25 mm 
silica gel plates. Melting points were determined in one end open 
capillary tubes using ANALAB melting point apparatus and were 
uncorrected. FT-IR spectra were recorded on a Shimadzu FTIR 
spectrophotometer. 1H NMR spectra were recorded on AVANCE 300 
MHz spectrometer using DMSO-d6 as solvent and tetramethyl silane 
(TMS) as an internal standard. All the 1H NMR Chemical shift values 
are recorded in δ scale. [13]C NMR spectra of synthesized 
compounds were recorded on Varian Gemini 100 MHz 
spectrophotometer. Mass spectra of the compounds were recorded 
on Agilent 6430 mass spectrophotometer. Elemental analysis was 
performed at Central University, Hyderabad, India. 
 
 
Scheme 1: The total synthetic pathway, reagents and conditions: (i) NH2OH. HCl, NaOH/CH3COONa, CH3OH, reflux 1-2 h; (ii) N-
Chlorosuccinamide, DMF, stirring 12 h; (iii) CH3COOC2H5, CH3OH, NaOH, stirring 1-2 h; (iv) 99 % NH2NH2. H2O, reflux 10-12 h; (v) 5-
bromoisatin, DMF, reflux 2-3 h 
 
Table 1: Derivatives of scheme 1 
Compound R R1 R2 R3 
6a OCH3 H H Br 
6b Cl H H Br 
6c F H H Br 
6d Cl Cl H Br 
6e OCH3 OCH3 H Br 
6f OH H H Br 
6g NO2 H H Br 
6h Br H  H Br 
6i CH3 H H Br 
6j CH3 H CH3 Br 
 
General procedure for synthesis of Ethyl 3-aryl-5-methyl-
isoxazole-4-carboxylates (4a-h) 
A methanolic solution of arylhydroxymoyl chloride (0.01 mol) was 
added in small portions to a solution of sodium salt of ethyl 
acetoacetete (0.02 mol) over a period of 1 h at 0-5 °C and 
subsequently stirred for 1h at room temperature by maintaining the 
pH 10 with aq. NaOH. The reaction was monitored by TLC. After 
completion of reaction, the mixture was poured into ice cold water 
and the solid separated was filtered and recrystallized from 90% 
ethanol. 
General procedure for synthesis of Ethyl 3-aryl-5-methyl-
isoxazolehydrazides (5a-h) 
To a solution of ethyl 3-aryl-5-methyl-isoxazole-4-carboxylate (0.01 
mol) in ethanol, was added hydrazine hydrate (99%, 0.04 mol) and 
heated to reflux for 10-12 h. The progress of the reaction was 
monitored by TLC. The reaction mixture was then poured into 
crushed ice drop by drop with constant stirring and the solid 
separated was filtered, dried and recrystallized from 90% ethanol. 
General procedure for synthesis of Ethyl (Z)-3-(3-aryl)-N'-(2-
oxoindolin-3-ylidene) isoxazole-4-carbohydrazides (6a-j) 
To a solution of ethyl 3-aryl-5-methyl isoxazolehydrazide (0.01 mol) 
in dimethylformamide (25 ml), 5-bromo isatin (0.01 mol) was added 
heated to reflux for 2-3 h. The progress of the reaction was 
monitored by TLC. The reaction mixture was then poured into 
crushed ice drop by drop with constant stirring. The solid separated 




Yield: 56 %. Red solid. mp: 190-196 °C. IR (KBr, cm-1): 3249, 3148 
(NH), 1689, 1663 (C=O), 1601 (CN). 1H NMR (300 MHz, CDCl3) δ: 
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12.6 (s, 1H, NH of isatin), 6.9-7.3 (7H, Ar), 6.0 (s, 1H, NH, 
exchangeable with D2O), 3.5 (s, 3H, OCH3), 2.9 (s, 3H, CH3). [13]C 
NMR: 175.7, 163.4, 160.2, 140.4, 136.4, 134.7, 132.6, 128.3, 121.6, 
119.6, 118.5, 118.2, 114.5, 111.1, 55.6, 13.0. MS (ESI): m/z 455 
[M+1]. HRMS calcd for C20H15BrN4O4 454.0276. Found454.0271. 
(Z)-N'-(6-bromo-2-oxoindolin-3-ylidene)-3-(4-chlorophenyl)-5-
methylisoxazole-4-carbohydrazide(6b) 
Yield: 67 %. Yellow solid. mp: 202-208 °C. IR (KBr, cm-1): 3486, 3239 
(NH), 1678, 1626 (C=O), 1600 (C=N), 752 (C-Cl). 1H NMR (300 MHz, 
CDCl3) δ: 12.9 (s, 1H, NH of isatin), 6.8-7.2 (7H, Ar), 6.8 (s, 1H, NH, 
exchangeable with D2O), 2.6 (s, 3H, CH3).). [13]C NMR: 175.4, 168.4, 
163.6, 162.8, 140.6, 136.7, 134.8, 134.0, 132.5, 129.4, 128.6, 127.4, 
119.2, 118.6, 118.0, 111.0, 13.0. MS (ESI): m/z 459 [M+1]. HRMS 
calcd for C19H12BrClN4O3 457.9781. Found 457.9784. 
(Z)-N'-(6-bromo-2-oxoindolin-3-ylidene)-3-(4-fluorophenyl)-5-
methylisoxazole-4-carbohydrazide(6c) 
Yield: 86 %. Yellow solid. mp: 169-174 °C. IR (KBr, cm-1): 3380, 3293 
(NH), 1683, 1616 (C=O), 1600 (CN). 1H NMR (300 MHz, CDCl3) δ: 
12.6 (s, 1H, NH of isatin), 6.8-7.2 (7H, Ar), 6.4 (s, 1H, NH, 
exchangeable with D2O), 2.8 (s, 3H, CH3). [13]C NMR: 175.4, 168.4, 
162.2, 163.6, 162.6, 140.4, 136.7, 134.5, 132.5, 130.4, 124.3, 119.4, 
118.4, 118.0, 116.2, 111.4, 13.0. MS (ESI): m/z 443 [M+1]. HRMS 
calcd forC19H12BrFN4O3442.0076. Found 442.0070. 
(Z)-N'-(6-bromo-2-oxoindolin-3-ylidene)-3-(3,4-
dichlorophenyl)-5-methylisoxazole-4-carbohydrazide (6d) 
Yield: 73 %. Pale yellow solid. mp: 186-192 °C. IR (KBr, cm-1): 3220, 
3196 (NH), 1700, 1626 (C=O), 1600 (CN), 755 (C-Cl). 1H NMR (300 
MHz, CDCl3) δ: 12.4 (s, 1H, NH of isatin), 7.0-7.6 (6H, Ar), 6.6 (s, 1H, 
NH, exchangeable with D2O), 2.9 (s, 3H, CH3). [13]C NMR: 
173.9,167.5, 163.4, 162.0, 140.6, 136.2, 
134.3,133.6,132.8,132.6,132.4,130.8,128.2,127.4,119.5,118.5,118.1,
111.8,13.0. MS (ESI): m/z 493 [M+1]. HRMS calcd for 
C19H11BrCl2N4O3 491.9391. Found 491.9396. 
(Z)-N'-(6-bromo-2-oxoindolin-3-ylidene)-3-(3,4-
dimethoxyphenyl)-5-methylisoxazole-4-carbohydrazide (6e) 
Yield: 72 %. Red solid. mp: 193-197 °C. IR (KBr, cm-1): 3336, 3241 
(NH), 1689, 1666 (C=O), 1600 (CN). 1H NMR (300 MHz, CDCl3) δ: 
12.8 (s, 1H, NH of isatin), 6.9-7.7 (6H, Ar), 6.0 (s, 1H, NH, 
exchangeable with D2O), 3.5 (s, 6H, OCH3), 2.4 (s, 3H, CH3). [13]C 
NMR: 175.2, 168.8, 163.6, 162.4,150.6, 149.6, 
140.4,137.2,134.6,132.8,126.6,120.1,119.4, 118.7, 118.2,111.8,111.2, 
108.8, 56.5, 13.0. MS (ESI): m/z 485 [M+1]. HRMS calcd 
forC21H17BrN4O5 484.0382. Found 484.0380. 
(Z)-N'-(6-bromo-2-oxoindolin-3-ylidene)-3-(4-hydroxyphenyl)-
5-methylisoxazole-4-carbohydrazide (6f) 
Yield: 80 %. Yellow solid. Mp: 170-175 °C. IR (KBr, cm-1): 3380, 3530 
(NH), 1680, 1662 (C=O), 1620 (CN). 1HNMR (300 MHz, CDCl3) δ: 
12.7 (s, 1H, NH of isatin), 6.7-8.1 (7H, Ar), 6.4 (s, 1H, NH, 
exchangeable with D2O), 4.5 (s, br, OH, exchangeable with D2O), 2.8 
(s, 3H, CH3). [13]C NMR: 174.9,168.2,163.6,162.4,158.8, 140.6,136.6, 
134.7,132.6, 128.6, 121.8, 119.5,118.6,118.0,116.2, 114.6, 111.0, 
13.0. MS (ESI): m/z 441 [M+1]. HRMS calcd for 
C19H13BrN4O4440.0120. Found 440.0122. 
(Z)-N'-(6-bromo-2-oxoindolin-3-ylidene)-5-methyl-3-(4-
nitrophenyl)isoxazole-4-carbohydrazide (6g) 
Yield: 72 %. Yellow solid. mp: 195-197 °C. IR (KBr, cm-1): 3438, 3196 
(NH), 1680, 1662 (C=O), 1602 (C=N), 1535, 1344 (NO2).1H NMR 
(300 MHz, CDCl3) δ: 12.8 (s, 1H, NH of isatin), 6.6-8.1 (7H, Ar), 6.4 (s, 
1H, NH, exchangeable with D2O), 2.9 (s, 3H, CH3).[13]C NMR: 175.4, 
168.1, 163.6, 162.0,147.2,140.6,136.8, 135.2,134.8, 
132.6,126.6,124.0,119.4,118.9,118.2,111.2,13.0. MS(ESI): m/z 
470[M+1]. HRMS calcd for C19H12BrN5O5 469.0021. Found 469.0027.  
(Z)-N'-(6-bromo-2-oxoindolin-3-ylidene)-3-(4-bromophenyl)-5-
methylisoxazole-4-carbohydrazide (6h) 
Yield: 67 %. Yellow solid. mp: 180-184 °C. IR (KBr, cm-1): 3220, 3195 
(NH), 1699, 1622 (C=O), 1602 (C=N). 1H NMR (300 MHz, CDCl3) δ: 
12.9 (s, 1H, NH of isatin), 6.8-7.8 (7H, Ar), 6.9 (s, 1H, NH, 
exchangeable with D2O), 2.8 (s, 3H, CH3). [13]C NMR: 175.4, 167.8, 
163.5, 140.2, 136.5, 134.7, 132.6, 132.4, 128.8, 128.0, 123.4, 119.5, 
118.6, 118.0, 111.9, 14.0. MS (ESI): m/z 503 [M+1]. HRMS calcd 
forC19H12Br2N4O3501.9276. Found 501.9271. 
(Z)-N'-(6-bromo-2-oxoindolin-3-ylidene)-5-methyl-3-(p-tolyl) 
isoxazole-4-carbohydrazide (6i) 
Yield: 82 %. Red solid. mp: 201-205 °C. IR (KBr, cm-1): 3348, 3238 
(NH), 1699, 1670 (C=O), 1600 (CN). 1H NMR (300 MHz, CDCl3): 12.7 
(s, 1H, NH of isatin), 6.9-7.7 (7H, Ar), 6.0 (s, 1H, NH, exchangeable 
with D2O),, 2.6 (s, 6H, CH3). [13]C NMR: 175.6, 168.2, 163.6, 162.4, 
141.5, 133.9, 131.9, 131.0, 129.7, 129.2, 126.0, 125.4, 123.8, 119.2, 
117.4, 111.4, 20.8, 13.0. MS (ESI): m/z 440 [M+1]. HRMS calcd for 
C20H15 BrN4O3 438.127. Found 438.1272.  
(Z)-N'-(6-bromo-2-oxoindolin-3-ylidene)-3-(2,4-
dimethylphenyl)-5-methylisoxazole-4-carbohydrazide(6j) 
Yield: 82 %. Red solid. mp: 220-225 °C. IR (KBr, cm-1): 3348, 3238 
(NH), 1699, 1670 (C=O), 1600 (CN). 1H NMR (300 MHz, CDCl3) δ: 12.7 
(s, 1H, NH of isatin), 6.9-7.7 (6H, Ar), 6.0 (s, 1H, NH, exchangeable with 
D2O), 2.8 (s, 3H, CH3), 2.6 (s, 6H, CH3). [13]C NMR: 174.4, 168.2, 163.6, 
161.9, 150.6, 149.2, 141.6, 134.8, 131.8, 129.6, 126.0, 124.8, 120.4, 
119.6, 117.5, 111.8, 111.0, 108.7, 56.4, 13.0. MS (ESI): m/z 407 [M+1]. 
HRMS calcd for C21H17BrN4O3 452.1277. Found 452.1272.  
2.3 In vitro VEGFR-2 kinase activity 
The in vitro enzyme inhibition assay for five selected compounds was 
carried out in Radiant Research Services Pvt. Ltd, Bangalore, India 
(http://www.radiantresearch.in/) at a single dose concentration of 5 
μM. VEGFR-2 (KDR, Lot # 061716 0713) (Ray BioR) has served as the 
enzyme source and Poly (Glu, Tyr) sodium salt, (4:1, Glu: Tyr) (Sigma 
Aldrich) served as the standardized substrate and Kinase-Glo Plus 
Luminescence kinase assay kit (PromegaTM) 
In vitro HUVEC anti-proliferative assay 
The In vitro HUVEC proliferative assay for four selected compounds 
was carried out by Radiant Research Pvt Ltd, Bangalore, India 
(http://www. radiantresearch. in/) at concentration of 500 nm, 1μM, 
2μM and 5μM. HUVEC (human umbilical vein endothelial cells) served 
as the cell source, in Medium 200 (Hi-Media), with large vessel 
endothelial supplement (LVES) (Life Technologies) and Pen-step (Hi-
Media). Alamar Blue (Hi-Media) was used as the fluorescent reagent. 
ADME and toxicity studies  
Compounds 6a, 6b, 6d and 6e are further studied for their 
pharmacokinetic and toxicity studies using ADMET descriptor 
analysis protocol in Discovery Studio. Using the standards provided 
by Discovery Studio, the results are analyzed. The calculated 
parameters are tabulated in the table 6.  
Molecular docking study 
Molecular docking is an effective technique to predict the preferred 
orientation of ligand molecules with a macromolecular target (protein 
receptor) when bound to each other to form a stable complex. The 
primary objective in molecular docking is its ability to estimate the 
scoring function and evaluate protein-ligand interactions in order to 
predict the affinity and activity of the ligand molecule. The docking 
program GOLD 3.1 was employed to generate different bioactive 
binding poses of designed molecules at the active site of protein 
VEGFR-2. Protein coordinates from the crystal structure were used to 
define the active site. Docking calculations were performed using the 
default GOLD fitness function and default GOLD parameters to 
produce the set of optimal conformations of both the ligand and the 
protein. The default parameters used are: population size ¼ 100; 
selection pressure ¼ 1.1; # operations ¼ 100,000; islands ¼ 5; inches 
size ¼ 2; migration ¼ 10; mutation ¼ 95; crossover ¼ 95. Each 
simulation is performed 10 times; yielding 10 docked conformations 
unless three of the 10 poses were within 1.5 A °RMSD of each other. 
The lowest energy conformations were regarded as the binding 
conformations between ligands and the receptor protein. The scoring 
function was used to reach optimal accuracy for candidate compound 
selection. The greater the GOLD fitness score, the better is the binding 
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affinity. Hit molecules which showed the expected interactions with 
the critical amino acids present in the active site of the protein, were 
selected as potent inhibitors of VEGFR-2. Using Define and Edit 
Binding Site tools in Accelrys Discovery Studio 2.1, the binding site of 
the VEGFR-2 domain (PDB: 4AG8) was predicted based on the 
occupied volume of the known ligand, Axitinib in the active site. The 
co-crystallized ligand, Axitinib molecule was first selected and a 
sphere was created around the molecule using define sphere for the 
selected option within the DS. The binding site containsVal914, 
Val916, Glu885, Ala866, Phe1047, Gly922, Leu1035, Glu917, Lys920, 
Cys1045, Cys919, Lys920. A sphere is defined around the residues 
comprising binding site at a radius of 10A °. 
 
 
Fig. 2: Ligand molecule 
 
RESULTS AND DISCUSSION 
Chemistry 
The synthetic route for the synthesis of final compounds is described 
under Scheme-1. Reaction of different aromatic aldehydes with 
hydroxylamine hydrochloride afforded corresponding oximes (1) 
which on treatment with N-chlorosuccinamide in DMF gave aryl 
hydroximoyl chlorides (2). The cyclization of compounds (2) with 
ethyl acetoacetate in methanol provided 3-aryl-5-methyl-isoxazole-4-
carboxylates (3) in reasonable yields. Conversion of compounds (3) 
into hydrazides was achieved by treating with hydrazine hydrate 
(99%) in methanol. Further, the coupling of hydrazides (5a-j) with 
isatin and 5-bromoisatinin in DMF afforded the final compounds (6a-
j). The characterization of intermediates and final compounds was 
done on the basis of FTIR, MASS, 1H NMR and [13]C NMR spectral data. 
In IR spectra, the final compounds (6a-j) showed the presence of two 
carbonyl absorption peaks around 1700 cm-1 and 1640 cm-1due to the 
carbonyl group of isatin and the carbonyl of hydrazide. Moreover, a 
sharp absorption band around 1600 cm-1was observed in all the 
spectra due to C=N stretching. In 1H NMR, the NH protons of isatin and 
amide appeared as singlets around δ 12.9 and δ 6.8. The three protons 
of methyl group appeared as singlet around δ 2.9 and as usual 
aromatic protons appeared in the range of δ 7.0-8.0. The appearance 
of molecular ion peaks corresponding to their molecular weights in 
mass spectra further confirmed the structures. Moreover, the different 
carbons present in the synthesized molecules were observed at the 
expected chemical shifts and integral values in 13C NMR spectra. 
Molecular docking 
Molecular docking study was carried out with the synthesized 
compounds into the ATP binding site of VEGFR-2 kinase enzyme 
(PDB: 4AG8) (Based on the occupied volume of known ligand 
Axitinib into the active site). The study was performed using GOLD 
3.1 software. Among sixteen compounds, compound 6d showed high 
fitness score of 56.19 with target protein VEGFR-2 through six 
bonding interactions involving five amino acids i. e, Asp 1046, Glu 
885, Lys 868, Phe 1047 and val 914 at the active site (fig. 4) through 
hydrogen bonding and vanderwall interactions, while the reference 
drug, semaxinib showed only two hydrogen bond interactions (Asp 
1046 and Phe 1047) with fitness score of 50.02 (fig. 3). The binding 
configuration of compound 6d shows that the substituted phenyl 
ring and isoxazole scaffold are very well lodged into the receptor 
pocket, while 4-chloro group is in hydrogen bonding interaction 
with Phe 1046. The C-21 of isoxazole showed interaction with Val 
914. The NH motif of amide moiety formed two hydrogen bonds 
with Asp 1046 and Glu 885. The nitrogen adjacent to the amide 
moiety also showed hydrogen bond interaction with Asp 1046. 
Compounds 6a,6b, 6d and 6e also exhibited good fitness scores of 
54.47, 52.38,56.19 and 52.07 and with 3 to 6 bonding interactions at 
the active site (fig. 5-7). The docking score results of all synthesized 
compounds (6a-j) are presented in table 2. 
 
 
Fig. 3–4: 3D images of molecular docking poses of semaxanib and compounds (6d) 
 
Table 2: Gold docking results of all synthesized compounds 
Compounds Fitness score S(hb_ext) S(vdw_ext) S(hb_int) S(int) 
6a 54.47 1.51 45.28 0.00 -9.29 
6b 52.38 1.49 41.14 0.00 -7.67 
6c 48.44 0.86 38.15 0.00 -4.87 
6d 56.19 1.69 44.44 0.00 -6.60 
6e 52.07 1.61 45.05 0.00 -11.48 
6f 47.28 1.57 39.84 0.00 -9.07 
6g 50.40 3.31 43.80 0.00 -9.64 
6h 51.51 2.00 41.66 0.00 -7.78 
6i 50.51 0.10 45.22 0.00 -11.78 
6j 50.75 2.55 41.90 0.00 -9.41 
Semaxinib 50.02 0.00 38.28 0.00 -2.61 
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In vitro VEGFR-2 kinase assay 
In molecular docking, compounds 6a, 6b, 6d, 6e and 6h 
demonstrated high fitness scores relative to the reference drug, 
semaxinib and were considered for in vitro VEGFR-2 kinase enzyme 
assay using a single dose concentration of 5 μM. The study was 
performed at Radiant Research Services Pvt. Ltd, Bangalore, India 
(http://www.radiantresearch.in/). The results revealed that the 
compound 6d has potent activity against VEGFR-2 kinase at 5 μM 
concentration with 86 % inhibition while the other compounds 6a, 
6e showed more than 75 %. However, Compound 6h exhibited 52 % 
inhibition and the results are presented in table 3. 
 
Table 3: Percent inhibition of VEGFR-2 enzyme activity 
Compounds R R1 R2 R3 % inhibition 
6a OCH3 H H Br 75 
6b Cl H H Br 72 
6d Cl Cl H Br 86 
6e OCH3 OCH3 H Br 78 
6h Br H H Br 52 
 
Based on (table 3) results, four compounds (6a, 6b, 6d and 6e)which 
exhibited above 70 % VEGFR-2 inhibition were selected for further dose-
related VEGFR-2 enzymatic inhibition at 500 nM, 1 μM, 2 μM and 4 μM 
concentrations in order to calculate their IC50 values (table 3). Two 
compounds 6d and 6a exhibited potent VEGFR-2 inhibitor activity with 
IC50 values of 1.33 μM and 1.75 μM while the reference drug semaxinib 
[20] showed IC50 value of 1.24 μM. However, compounds 6a and 6d 
exhibited reasonable activity. A good correlation was observed among 
the studies of molecular docking, in vitro VEGFR-2 kinase enzyme assay 
and in vitro IC50 values. The IC50 values are presented in the table 4. 
 
Table 4: The IC50 values of selected compounds based on VEGFR-2 inhibition 
Compounds VEGFR-2 (% inhibition) VEGFR-2 (IC50) 
6a 78 1.75 
6b 72 2.18 
6d 86 1.33 
6e 70 2.33 
semaxinib 98 1.24 
 
In vitro antiproliferative assay 
For antiproliferative assay, HUVEC cell line was selected since they 
play a major role in angiogenesis or new blood vessel formation. 
Four compounds (6a, 6b, 6d and 6e) that demonstrated more than 
70 % VEGFR-2 inhibition were selected for their activity against 
HUVEC cell line at a single dose concentration of 10 µM. In screening, 
the compounds exhibited varied antiproliferative activity. 
Compounds 6d and 6e showed good antiproliferative activity with 
percentage inhibition of 78 % and 98 %, while the compounds 6a 
and 6b exhibited 72 % and 70 % and the reference semaxinib 
showed 100% inhibition. These values are in good correlation with 
the in vitro VEGFR-2 enzyme inhibitory assay. The results are shown 
in table 5. 
 
Table 5: The effect of compounds on HUVEC cell line at 10 µM 
Compounds %Cell growth %Cell inhibition 
6a 28.69 72 
6b 50.06 70 
6d 30.02 78 
6e 0.65 98 
semaxinib 0.29 100 
 
 
Fig. 5: Plot of PSA versus Log P for candidate compounds showing the 95% and 99% confidence limit ellipses corresponding to the blood–
brain barrier and intestinal absorption models ADME and toxicity studies  
Radhika et al. 




The ADMET studies deal with in silico prediction of the adverse effects 
of the synthesized compounds. The properties such as absorption, 
distribution, metabolism, excretion and toxicity (ADMET) are 
important in order to determine the success of the compound for 
human therapeutic use. The results were compared to the reference 
Level values of Discovery Studio to analyse the properties of our 
compounds. The absorption levels (human intestinal absorption) of all 
the compounds are predicted to be having good absorption. The 
solubility levels of the compounds were in the range of 1–2, indicating 
good solubility. BBB penetration of all the compounds are 3 and 4, the 
values represent high penetration of the compounds. All the 
compounds exhibited in silco cytochrome P450 2D6 inhibition. Similarly, 
all the compounds are satisfactory with respect to CYP2D6 value is 
near to 0, suggesting that these compounds should be non-inhibitors 
of CYP2D6. The plasma protein binding property prediction denotes 
that all of them have binding ≥95% indicating that most of the 
compounds have good bioavailability and are not likely to be highly 
bound to carrier proteins in the blood. Further, all the compounds 
have been predicted to have the probable hepatotoxic levels less than 
1. Of all the compounds, compound 6a showed least probability value 
of 0.894 suggesting that this compound is least toxic compared to all 
the compounds. The results are shown in table 6. 
 
Table 6: Absorption, distribution, metabolism, excretion and toxicity (ADMET) of synthetic derivatives 
Name BBB_ 
level 







Axitinb 1 0 2 0.96 1 0.613 4.492 
Comp. 6a 4 0 2 0.894 2 0.366 3.026 
Comp. 6b 4 0 1 0.927 2 0.198 4.388 
Comp. 6d 3 0 2 0.933 2 0.297 3.639 
Comp. 6e 4 0 2 0.913 2 0.336 3.043 
 
CONCLUSION 
Ten novel isatin incorporated isoxazole derivatives were designed 
and synthesized by the condensation of different 3-aryl-5 
methylisoxazole-4-carbohydrazides (5a-j) with 5-bromoisatin in 
order to give the target compounds that act as VEGFR-2 inhibitors. 
The synthesized compounds were characterized on the basis of 
spectral and elemental analysis data. In molecular docking, all the 
designed compounds (6a-j) exhibited high fitness scores with 
minimum three bonding interactions with the active site of VEGFR-2 
kinase. In in vitro VEGFR-2 kinase enzyme assay, compounds 6a, 6b, 
6d and 6e exhibited more than 70% inhibition at a single dose 
concentration of 5 µM. In antiproliferative assay against HUVEC cell 
line, compounds 6d and 6e exhibited potent activity with IC50 values 
in nanomolar (μm) concentrations. ADMET results of 6a, 6b, 6d and 
6e are quite promising with least hepatotoxicity and good 
bioavailability. 
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